Based in Sweden IRLAB Therapeutics is developing novel drugs for the treatment of neurodegenerative diseases, focusing on PD, utilising its proprietary ISP technology platform. Its two lead assets are in late-stage clinical trials: mesdopetam (D3 antagonist for PD-LIDs) and pirepemat (PFC enhancer for impaired balance and falls).
IRLAB Therapeutics is focused on developing novel, potential first-in-class treatments for the symptoms of Parkinson’s disease (PD) and other CNS disorders. Its proprietary ISP discovery platform has been validated by the progress of its two lead assets, pirepemat and mesdopetam, which have novel mechanisms of action. Pirepemat is an oral prefrontal cortex enhancer in a phase IIb trial for the treatment of impaired balance and falls in PD. Mesdopetam is an oral D3 antagonist has just completed recruitment in a Phase IIb trial for levodopa-induced dyskinesias (PD-LIDs) and top line data are anticipated at the year end. In 2021 Ipsen acquired a global licence (worth up to $363m plus royalties) for the future clinical development and commercialisation of mesdopetam. In addition to pirepemat IRLAB is developig a preclinical pipeline of drug candidates (IRL942 and IRL757) for the non motor symptoms of PD and a potential one a day treatment for PD without complications (P003). The company remains well funded in the medium term.
PD is characterised by a triad of cardinal motor symptoms, although non-motor symptoms are as debilitating and remain undertreated. Despite substantial efforts to develop disease-modifying approaches in PD, symptomatic treatment remains the mainstay.